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INTRODUCTION
The most frequent primary intraocular malignancies are: uveal melanoma
in adults and retinoblastoma in children. The natural history of choroidal
melanoma (MM-CH) is variable and not fully delineated. The diagnostic
challenges are the differentiation of MM-CH from choroidal nevus,
choroidal metastasis, choroidal hemangiomas, subchoroidal hematomas
and exudative form of age-related macular degeneration(1). The diagnosis
can usually be made by slit lamp biomicroscopy or indirect ophthalmoscopy.
The use of other diagnostic methods such as fluorescein angiography,
ultrasonography, magnetic resonance imaging and fine needle biopsy can
occasionally be used to establish the diagnosis in atypical cases(2).
The management of MM-CH has been the subject of considerable
controversy and treatment methods include enucleation and other
techniques designed to preserve the eye, such as local resection, plaque
radiotherapy, charged particle radiotherapy, laser photocoagulation, and
thermotherapy. Eye conservation can be achieved in these patients by
several techniques, with external beam charged particle (proton) therapy
and episcleral plaque therapy being used most commonly for MM-CH.
The probability of visual preservation and of eye retention with
either technique is related to tumor size and location(3). The useful vision is
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preserved in eyes with tumors occurring in a favorable loca-
tion with respect to the optic disc or macula, but an average of
16.3% of patients treated with radiotherapy subsequently re-
quire enucleation due tumor regrowth or uncontrollable neo-
vascular glaucoma(4).
Many series have shown that patients with MM-CH were
diagnosed too late and in these cases enucleation was the
preferred method of treatment(4-5), but the current emphasis is
organ preservation with total or partial visual sparing(6).
At the Hospital A. C. Camargo, we started a conservative
treatment policy since January, 1989 using Stallard Cobalt-60
plaques for MM-CH. To date there are 287 patients treated,
including MM-CH, retinoblastoma, hemangioma and intrao-
cular metastasis.
METHODS
This is a retrospective analysis conducted at the "Centro
de Tratamento e Pesquisa – Hospital do Câncer”, São Paulo,
Brazil. From January, 1995 to June, 1999 there were 132 pa-
tients with intraocular tumors consecutively treated at the
Brachytherapy Service and Onco-ophthalmology Department
and of these, 108 had MM-CH.
Of the total of patients presenting MM-CH, 102 had ocular
confined disease and 6 extraocular extensions and were
excluded from the analysis. All patients had a minimum follow-
up of 24 months and were evaluated regarding tumor characte-
ristics, treatment times, doses to the apex and base of tumor
and clinical outcome.
Survival analysis was performed using Kaplan-Meier esti-
mates and differences in quantitative variables through chi-
square tests(7).
All patients were diagnosed by slit lamp biomicroscopy,
indirect ophthalmoscopy and ultrasonography. Pulmonary,
bone and liver scan were performed in selected suspicious
cases. There was no fine needle biopsy used for diagnosis in
this group of patients.
RESULTS
Median age of patients was 55.5 years (range15 to 85).
There was a slight predominance of males (54/48) and left-
sided (52/50) lesions.
Median tumor base size was 9.75 mm (range 5 to 15 mm) and
median apex size was 5 mm (range 2 to 13 mm), determined by
ultrasound. There was a predominance of peripheral (72 ca-
ses) over central or paracentral (30 cases) lesions.
Patients were admitted to the hospital for an average of 6 days
(range 3 to 16) with positioned plaques. Doses at the base of the
tumor, including 1 mm of sclera, ranged from 157 to 487 Gy (median
284.5 Gy) and to the apex from 37 to 220 Gy (median 106 Gy) (Table 1).
The crude eye preservation rate with conservative therapy
alone was 78.5%. Twenty-two (21.5%) patients presented lo-
cal uncontrolled disease after a median follow-up of 34 months
Table 1. Characteristics of patients
Variable Mean Median Range
Age (years) 50.4 55.5 15 - 85
Base size (mm) 10.0 9.7 5 - 15
Apex size (mm) 5.8 5.0 2 - 13
Base dose (Gy) 298.2 284.5 157 - 487
Apex dose (Gy) 113.6 106.0 37 - 220
Stay in hospital (days) 6.7 6.0 3 - 16
(range 19-64), and underwent enucleation. The 5-year overall
actuarial survival rate was 92.2% (Figure 1) and eye conserva-
tion rate was 78% (Figure 2).
The differences in the size of the tumor base, apex, dose to
the apex and treatment days were not statistically significant
predictors of clinical outcome in this analysis (Table 2). The
dose given to the tumor base was the most important factor to
determine a favorable clinical outcome, but without statistical
significance (p=0.075).
Central or paracentral tumors showed 50% of the prethera-
peutic vision after 2 years, and 80% of the vision was preser-
ved in those with peripheral tumors. The main side effects
were mostly an uncomplicated retinopathy in 39/102 patients
(38.2%); macular degeneration or scarring led to poor central
vision in 31/102 patients (30.3% of cases).
After completion of treatment patients were evaluated every
4 months in the first year and every six months thereafter. In the
follow-up examinations such as serial photographs, ultrasound,
and transillumination, among others, were performed.
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Figure 1 - Kaplan-Meier: overall survival analysis
Years
Survival function              Censored
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Table 2. Tumor and treatment variables and clinical outcome.
Univariate analysis
Status
Variable NED Enucleated p
Base size < 6 1 -
(mm) > 6 < 9 18 3
> 9 < 12 28 9        0.804
>12 33 10
Apex size < 5 37 11
(mm) > 5 < 8 30 3
> 8 < 12 10 7        0.892
>12 3 1
Base dose < 200 4 -
(Gy) > 200 < 250 18 5
> 250 <  300 27 6
> 300 < 350 22 5        0.075
> 350 < 400 4 2
> 400 5 4
Apex dose < 40 5 3
(Gy) > 40 < 60 16 3
> 60 < 80 15 6        0.179
> 80 < 100 16 2
> 100 28 8
Treatment < 4 7 2
(days) > 4 < 8 53 14         0.989
> 8 < 10 11 2
> 10 9 4
Total 80 22
NED - no evidence of disease in activity
DISCUSSION
Enucleation as a standard treatment for choroidal melano-
ma has been questioned since the sixties, because of the loss
of sight on that side and the nearly 50% death rate at five
years due to metastases(8).
As none of the different treatments, enucleation or brachy-
therapy offer a survival advantage, a key factor in choosing
among treatment options is their differential impact on the
patients’ quality of life.
Of interest is a recent survey reporting that the choice of
treatment for uveal melanoma did not seem to be associated
with large differences in quality of life when assessed at long-
term follow-up(1).
The reduction of the lesion depends on individual charac-
teristics of the tumor and must be recorded individually. Pa-
tients who are submitted to conservative treatment, if they
have a regrowth of the lesions after brachytherapy, to record
it with serial photographs, ultrasound, and transillumination
is suggested. In a series of 82 MM-CH treated with brachythe-
rapy (cobalt-60 and iodine-125), the serial ultrasonic measure-
ments showed that no two patients had identical patterns of
change. The mean absolute change in tumor height after treat-
ment was 1.8 mm at six months, 5.6 mm at 48 months for large
tumors, and 0.9 and 1.9 mm for medium sized tumours(9).
A publication evaluating the rate and extent of regression
of the first 100 consecutive patients with a MM-CH managed
by Cobalt-60 brachytherapy, reported that half of the lesions
did not regress rapidly to a flat, depigmented scar but shrank
slowly and persisted as a residual mass with approximately
50% of the thickness of the original tumor at 54 months follo-
wing brachytherapy(10).
Another report of 62 patients with local relapse, who were
matched with an equal number of relapse-free patients in terms
of known clinical prognostic factors for both MM-CH specific
mortality and local tumor relapse, estimated a 5-year actuarial
survival of 87% versus 58% for relapsed patients(11).
In a recent publication no large difference in MM-CH-
specific 15-year mortality rate was observed, in patients treated
by enucleation versus brachytherapy, after eliminating indivi-
dual clinical variables(12).
In our experience, Co-60 plaque brachytherapy has achie-
ved a satisfactory rate of tumor local control, despite the over-
sized base diameters of treated tumors.
The relative high incidence of presented side effects may be
due the used isotope Cobalt-60, a gamma emitter (median energy
-1.25 MV) with a relative lack of shielding, with greater amount of
intraocular and extraocular tissue being exposed to high doses of
radiation when compared to other isotope applicators.
In our analysis we observed a trend toward to a higher dose
to the tumor base related to local control, which did not corre-
late with a higher incidence of side effects. On the other hand,
treatment outcome did not seem to be improved by increasing
the apical dose.
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Figure 2 - Kaplan-Meier: eye preservation estimates
Years
Survival function              Censored
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Currently, I-125 and Ru106 are preferred because their lower
energy allows easy shielding, leading to better radiation pro-
tection for personnel, intra- and extraocular normal tissue(13).
CONCLUSION
Our experience with cobalt-60 plaque brachytherapy
achieved a satisfactory rate of local tumor control, despite the
oversized base diameters of tumors treated.
RESUMO
Objetivos: Para avaliar o resultado de tratamento pacientes
portadores de melanoma de coróide tratados com braquitera-
pia (placas episclerais de Co-60) no Hospital do Câncer, São
Paulo, Brasil. Métodos: Foram avaliados 108 pacientes trata-
dos consecutivamente de janeiro de 1995 a junho de 1999, com
idade mediana de 55,5 anos, diâmetro da base do tumor e altura
máximos 9,75 mm e 5 mm, respectivamente. As doses na base
do tumor, incluindo 1 mm de esclera variaram de 157 a 487 Gy
(mediana 284,5 Gy) e para o ápice de 37 até 220 Gy (mediana
106 Gy). Resultados: A taxa de preservação ocular foi 78,5%,
com sobrevida atuarial global em cinco anos, e a taxa de con-
servação ocular atuarial foram 92,2% e 78%, respectivamente.
Os principais efeitos colaterais relacionados ao tratamento
foram retinopatia em 39/102 (38,2%) pacientes e degeneração
macular, levando a déficit visual central em 31/102 (30,3%)
pacientes. Conclusão: Nossa experiência com placas episcle-
rais de Co-60 alcançou taxa satisfatória de controle de tumor
local, apesar dos grandes diâmetros das bases dos tumores.
Descritores: Neoplasias da coróide; Melanoma; Radioisóto-
pos de cobalto/uso terapêutico; Enucleação ocular; Braquite-
raia; Dosagem radioterapêutica
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